Quarterly report · Q2
3151.TEDINET S100PL90
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥289.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥577.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥285.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥730m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥934m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥316.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥313.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥327.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥212.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥213.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥103.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥105.6bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥23.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.4bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥27.42 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.4 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.67 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.01 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥146m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥6.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥6.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥278.2bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥273.0bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥607m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥32m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥178m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥292.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥287.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥819m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥295.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥289.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥672m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥97m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥5.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥5.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | ¥19m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥273.4bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥269.1bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥739m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥83m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥189m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥287.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥283.3bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.3bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥290.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥285.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥915m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Other comprehensive income | Prior1YTDDuration | 919000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 3841000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 2385000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 5328000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 2330000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 5279000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 55000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 49000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 2280000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 2350000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 1335000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 1460000000 | JPY |
| Impairment loss ope cf | Prior1YTDDuration | 47000000 | JPY |
| Impairment loss ope cf | CurrentYTDDuration | 22000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 171000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 171000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -20000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | 660000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | -85000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | -60000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | -293000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -2093000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -433000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -419000000 | JPY |
| Rent income ope cf | Prior1YTDDuration | -124000000 | JPY |
| Rent income ope cf | CurrentYTDDuration | -113000000 | JPY |
| Office work fee ope cf | Prior1YTDDuration | -765000000 | JPY |
| Office work fee ope cf | CurrentYTDDuration | -790000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 48000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 51000000 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YTDDuration | -14000000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYTDDuration | -27000000 | JPY |
| Loss gain on sales and valuation of investment securities ope cf | Prior1YTDDuration | 8000000 | JPY |
| Loss gain on sales and valuation of investment securities ope cf | CurrentYTDDuration | -3000000 | JPY |
| Loss gain on sales and retirement of property plant and equipment ope cf | Prior1YTDDuration | 8000000 | JPY |
| Loss gain on sales and retirement of property plant and equipment ope cf | CurrentYTDDuration | -13000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -6589000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -4036000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -2089000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | 344000000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1YTDDuration | -132000000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYTDDuration | 713000000 | JPY |
| Decrease increase in guarantee deposits ope cf | Prior1YTDDuration | 49000000 | JPY |
| Decrease increase in guarantee deposits ope cf | CurrentYTDDuration | 4301000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 10330000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 2563000000 | JPY |
| Other net ope cf | Prior1YTDDuration | -176000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -794000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 3556000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 4285000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |